Home » Stocks » Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. (CRNX)

Stock Price: $15.29 USD -0.29 (-1.86%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 502.21M
Revenue (ttm) 897,000
Net Income (ttm) -58.77M
Shares Out 32.85M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $15.29
Previous Close $15.58
Change ($) -0.29
Change (%) -1.86%
Day's Open 15.55
Day's Range 15.10 - 16.15
Day's Volume 177,576
52-Week Range 10.63 - 26.67

More Stats

Market Cap 502.21M
Enterprise Value 393.56M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.85M
Float 16.50M
EPS (basic) -2.42
EPS (diluted) -2.42
FCF / Share -2.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.54M
Short Ratio 7.83
Short % of Float 5.77%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 559.88
PB Ratio 5.22
Revenue 897,000
Operating Income -61.57M
Net Income -58.77M
Free Cash Flow -52.00M
Net Cash 108.65M
Net Cash / Share 3.31
Gross Margin -4,494.20%
Operating Margin -6,863.99%
Profit Margin -6,551.40%
FCF Margin -5,796.66%
ROA -26.48%
ROE -45.06%
ROIC -74.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(140.68% upside)
Current: 15.29
Target: 36.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-50.86%18.73%247.2%-
Gross Profit1.192.432.050.59
Operating Income-53.83-28.71-9.13-6.04
Net Income-50.42-27.12-9.16-6.02
Shares Outstanding24.1812.141.371.01
Earnings Per Share-2.09-2.23-6.68-5.96
Operating Cash Flow-46.38-19.46-9.48-5.47
Capital Expenditures-0.49-1.06-0.30-0.19
Free Cash Flow-46.87-20.52-9.78-5.66
Cash & Equivalents11916414.1912.15
Total Debt4.85--0.21
Net Cash / Debt11416414.1911.94
Book Value117160-15.02-6.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Crinetics Pharmaceuticals, Inc.
Country United States
Employees 68
CEO Scott R. Struthers

Stock Information

Ticker Symbol CRNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRNX
IPO Date July 18, 2018


Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.